President Donald Trump announced on Friday that all 50 states, the District of Columbia, and Puerto Rico have opted into his Most Favored Nation drug-pricing initiative to lower prescription costs for roughly 70 million Medicaid recipients. According to the White House, the policy matches federal agency rates with those paid in eight other high-income nations, including Canada, Germany, Japan, and the United Kingdom, unlocking projected Medicaid drug savings of $64 billion over the next decade.
How the Most Favored Nation Medicaid Model Works
The program, officially dubbed the Medicaid “GENEROUS” model according to the Associated Press, relies on agreements struck with 26 major pharmaceutical companies. As reported by the White House, these participating drugmakers cover 90% of the branded U.S. market. By aligning domestic prices with rates in affluent nations, the initiative aims to reduce the net price of selected drugs for state-administered Medicaid programs. Patients enrolled in Medicaid already pay nominal co-payments of a few dollars, but administration officials argue the lower prices will deliver substantial relief to state budgets.
Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz stated that state budgets are being rescued by the program. According to Oz, the $50 billion in pharmaceutical prices that states are paying after rebates has previously crowded out funding for schools, roads, long-term care, and rural care. President Trump told reporters in the Oval Office that the initiative would save states billions of dollars annually, enabling them to reinvest those funds into better healthcare and higher quality services.
Projected Savings and Transparency Concerns
Estimates regarding the financial impact of the Most Favored Nation rollout vary between official projections and independent analysis. According to White House economic advisers cited in administration releases, the broader Most Favored Nation initiative is projected to save the government $529 billion over a decade, while the specific Medicaid agreements will yield $64 billion over the same period. In addition, the separate TrumpRx platform has already delivered more than $700 million in savings for Americans without insurance, according to official figures.
However, independent policy experts point out that verifying these figures remains challenging. Kathy Hempstead, a senior policy adviser at the Robert Wood Johnson Foundation, told the Associated Press that the true cost of the claimed savings is unclear because the content of the deals struck by the administration and pharmaceutical companies has not been made public. Hempstead noted that the lack of granular data creates a barrier to legislative action and raises questions about the long-term durability of the price cuts if future administrations change course.
Defending the administration’s approach, White House spokesman Kush Desai pointed to drug deals negotiated during former President Joe Biden’s term under the Inflation Reduction Act that similarly omitted commercially sensitive information. Desai stated that experts questioning the administration’s transparency on the same grounds should be regarded as partisan or uninformed.
Pro Tip: Tracking Medication Costs
Patients seeking affordable prescriptions can check platforms like TrumpRx to see if specific branded or generic medications qualify for discounted pricing outside of traditional insurance structures.
Political Reactions and the Midterm Landscape
The nationwide participation announcement arrives as cost-of-living issues dominate voter concerns ahead of the November midterm elections. President Trump remarked during the Oval Office announcement that the drug-pricing achievement alone should win his party the midterms, noting that while left-wing critics predicted states would not participate, even reluctant blue states ultimately joined due to getting your drugs for far less.
Health and Human Services Secretary Robert F. Kennedy Jr. endorsed the program as a realization of long-standing priorities regarding society’s poorest members. Kennedy stated that President Trump has achieved historic drops in poverty levels and created a giant benefit for vulnerable populations. Meanwhile, industry figures note that work remains. JD Hayworth, a former Republican congressman and spokesperson for the Pharmaceutical Reform Alliance, said in a statement reported by the Associated Press that the announcement reflects meaningful progress, but noted that millions of uninsured or commercially insured Americans outside government healthcare programs still seek broader relief from rising health costs.
Did You Know?
According to White House data, prescription drug prices recorded their sharpest annual drop in more than 60 years during 2026, falling every month.
Frequently Asked Questions
What is the Most Favored Nation drug pricing initiative?
According to the White House, it is a federal policy capping prices for medications in the U.S. to match the lowest rates paid in eight other high-income nations, including Canada, Germany, Japan, and the U.K.
Do all 50 states participate in the Medicaid drug model?
Yes. President Trump announced on Friday that all 50 states, the District of Columbia, and Puerto Rico have opted into the program.
How much money is the program expected to save?
The White House estimates that extending the pricing model to Medicaid will save states $64 billion over the next 10 years, while the broader federal initiative is projected to save $529 billion over the same period.
Can independent experts verify these savings?
According to the Associated Press, independent experts note that verifying the projected savings is difficult because exact details and terms of the deals struck with pharmaceutical companies have not been made public.
Want to stay updated on major policy shifts affecting healthcare costs and state budgets? Subscribe to our morning newsletter for daily news delivered directly to your inbox, or explore more coverage in our politics section.
Worth a look